RAPP
Rapport Therapeutics, Inc.
Price Chart
Latest Quote
$37.34
+0.47 (+1.27%)
Current Price
| Previous Close | $36.87 |
| Open | $37.75 |
| Day High | $38.12 |
| Day Low | $36.46 |
| Volume | 339,144 |
Stock Information
| Shares Outstanding | 47.83M |
| Total Debt | $10.80M |
| Cash Equivalents | $476.78M |
| Revenue | $20.00M |
| Net Income | $-107.28M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.79B |
| EPS (TTM) | $-2.60 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.32B |
| Sales | $20.00M |
| Income | $-107.28M |
| Book/sh | $9.86 |
| Cash/sh | $9.97 |
| Employees | 84 |
Financial Ratios
| Quick Ratio | 26.64 |
| Current Ratio | 27.08 |
| Debt/Eq | 2.29 |
Returns & Margins
| ROA | -19.10% |
| ROE | -28.33% |
| Gross Margin | 34.28% |
| Operating Margin | -121.08% |
Ownership
| Insider Ownership | 4.65% |
| Institutional Ownership | 117.11% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -8.36 |
| P/S | 89.29 |
| P/B | 3.79 |
Analyst Data
| Recommendation | none |
| Target Price | $57.10 |
Technical Indicators
| SMA20 | $37.38 |
| SMA50 | $36.72 |
| SMA200 | $29.91 |
| RSI | 43.37 |
| ATR | 2.4176 |
| Shares Float | 31.76M |
| Short Float | 8.15% |
| Short Ratio | 7.67 |
| Volatility | 0.98 |
| Rel Volume | 1.17 |
Performance History
| Week | +6.05% |
| Month | +8.64% |
| Quarter | +35.98% |
| 6 Months | +21.39% |
| YTD | +32.84% |
| Year | +241.00% |
| 10 Years | +79.52% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $37.34 | 355,400 |
| 2026-06-17 | $36.87 | 273,500 |
| 2026-06-16 | $38.49 | 157,100 |
| 2026-06-15 | $38.26 | 315,800 |
| 2026-06-12 | $38.40 | 255,600 |
| 2026-06-11 | $35.21 | 1,063,300 |
| 2026-06-10 | $35.21 | 344,600 |
| 2026-06-09 | $35.84 | 256,700 |
| 2026-06-08 | $36.68 | 151,200 |
| 2026-06-05 | $36.10 | 181,300 |
| 2026-06-04 | $37.49 | 204,000 |
| 2026-06-03 | $37.00 | 198,600 |
| 2026-06-02 | $34.90 | 309,400 |
| 2026-06-01 | $37.11 | 256,400 |
| 2026-05-29 | $39.50 | 345,600 |
| 2026-05-28 | $39.49 | 187,700 |
| 2026-05-27 | $39.51 | 270,200 |
| 2026-05-26 | $39.71 | 438,100 |
| 2026-05-22 | $37.72 | 174,200 |
| 2026-05-21 | $36.70 | 321,000 |
| 2026-05-20 | $35.72 | 260,100 |
| 2026-05-19 | $34.37 | 307,000 |
About Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.
đ° Latest News
Is Rapport Therapeutics, Inc. (RAPP) A Good Stock To Buy Now?
Insider Monkey âĸ 2026-06-16T15:08:56Z
Is Rapport Therapeutics (RAPP) Using RAP-219 To Redefine Its Broader Neuroscience Investment Narrative?
Simply Wall St. âĸ 2026-06-08T02:08:52Z
BTIG Raises its Price Target on Rapport Therapeutics (RAPP)
Insider Monkey âĸ 2026-06-05T21:03:31Z
Rapport Therapeutics, Inc. (RAPP) Reports Q1 Loss
Zacks âĸ 2026-05-07T12:50:04Z
Rapport Therapeutics Insiders Added US$1.61m Of Stock To Their Holdings
Simply Wall St. âĸ 2026-04-30T13:04:21Z
Rapport Insider Sells $17.2 Million as Stock Surges 230% in a Year and Phase 3 Trials Near
Motley Fool âĸ 2026-04-27T20:17:56Z
All You Need to Know About Rapport Therapeutics, Inc. (RAPP) Rating Upgrade to Buy
Zacks âĸ 2026-03-26T16:00:03Z
How Investors May Respond To Rapport Therapeutics (RAPP) Licensing RAP-219 To Tenacia In Greater China
Simply Wall St. âĸ 2026-03-21T00:17:06Z
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal
Motley Fool âĸ 2026-03-16T23:33:01Z
Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch
Motley Fool âĸ 2026-03-16T23:02:12Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenue | |||
| Total Revenue | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 |
| Expenses | |||
| Total Expenses | $125,099,000 | $83,055,000 | $36,179,000 |
| Net Non Operating Interest Income Expense | $13,616,000 | $12,138,000 | $2,527,000 |
| Operating Expense | $125,099,000 | $83,055,000 | $36,179,000 |
| General And Administrative Expense | $30,310,000 | $22,120,000 | $8,180,000 |
| Other Income Expense | - | $-7,390,000 | $-1,124,000 |
| Other Non Operating Income Expenses | - | $-7,390,000 | $-1,124,000 |
| Interest Expense | - | - | $0 |
| Interest Expense Non Operating | - | - | $0 |
| Income & Earnings | |||
| Net Income From Continuing Operation Net Minority Interest | $-111,483,000 | $-78,307,000 | $-34,786,000 |
| Net Interest Income | $13,616,000 | $12,138,000 | $2,527,000 |
| Interest Income | $13,616,000 | $12,138,000 | $2,527,000 |
| Normalized Income | $-111,483,000 | $-78,307,000 | $-34,786,000 |
| Net Income From Continuing And Discontinued Operation | $-111,483,000 | $-78,307,000 | $-34,786,000 |
| Total Operating Income As Reported | $-125,099,000 | $-83,055,000 | $-36,179,000 |
| Net Income Common Stockholders | $-111,483,000 | $-78,307,000 | $-34,786,000 |
| Net Income | $-111,483,000 | $-78,307,000 | $-34,786,000 |
| Net Income Including Noncontrolling Interests | $-111,483,000 | $-78,307,000 | $-34,786,000 |
| Net Income Continuous Operations | $-111,483,000 | $-78,307,000 | $-34,786,000 |
| Pretax Income | $-111,483,000 | $-78,307,000 | $-34,776,000 |
| Interest Income Non Operating | $13,616,000 | $12,138,000 | $2,527,000 |
| Operating Income | $-125,099,000 | $-83,055,000 | $-36,179,000 |
| Per Share | |||
| Diluted EPS | $-2.86 | $-3.78 | $-23.10 |
| Basic EPS | $-2.86 | $-3.78 | $-23.10 |
| Other | |||
| Tax Effect Of Unusual Items | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-124,082,000 | $-82,216,000 | $-36,067,000 |
| Reconciled Depreciation | $1,017,000 | $839,000 | $112,000 |
| EBITDA (Bullshit earnings) | $-124,082,000 | $-82,216,000 | $-36,067,000 |
| EBIT | $-125,099,000 | $-83,055,000 | $-36,179,000 |
| Diluted Average Shares | $38,934,569 | $20,738,338 | $1,505,774 |
| Basic Average Shares | $38,934,569 | $20,738,338 | $1,505,774 |
| Diluted NI Availto Com Stockholders | $-111,483,000 | $-78,307,000 | $-34,786,000 |
| Research And Development | $94,789,000 | $60,935,000 | $27,999,000 |
| Selling General And Administration | $30,310,000 | $22,120,000 | $8,180,000 |
| Other Gand A | $8,791,000 | $8,131,000 | $3,856,000 |
| Salaries And Wages | $21,519,000 | $13,989,000 | $4,324,000 |
| Tax Provision | - | $0 | $10,000 |
| Total Unusual Items | - | - | $-1,124,000 |
| Total Unusual Items Excluding Goodwill | - | - | $-1,124,000 |
| Gain On Sale Of Security | - | - | $-1,124,000 |
Fetched: 2026-06-18
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $484,653,000 | $305,427,000 | $-25,634,000 | $-10,062,000 |
| Total Assets | $512,431,000 | $314,933,000 | $155,423,000 | $31,603,000 |
| Total Non Current Assets | $13,870,000 | $5,131,000 | $4,551,000 | $335,000 |
| Other Non Current Assets | $985,000 | $160,000 | $551,000 | - |
| Current Assets | $498,561,000 | $309,802,000 | $150,872,000 | $31,268,000 |
| Other Current Assets | $7,917,000 | $4,417,000 | $3,309,000 | $109,000 |
| Restricted Cash | $105,000 | $105,000 | $85,000 | $0 |
| Cash Cash Equivalents And Short Term Investments | $490,539,000 | $305,280,000 | $147,478,000 | $31,159,000 |
| Cash And Cash Equivalents | $52,645,000 | $56,805,000 | $70,169,000 | $31,159,000 |
| Debt | ||||
| Total Debt | $11,484,000 | $1,476,000 | $2,146,000 | $0 |
| Long Term Debt And Capital Lease Obligation | $8,729,000 | $739,000 | $1,476,000 | $0 |
| Current Debt And Capital Lease Obligation | $2,755,000 | $737,000 | $670,000 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $27,778,000 | $9,506,000 | $181,057,000 | $41,665,000 |
| Total Non Current Liabilities Net Minority Interest | $8,729,000 | $739,000 | $172,254,000 | $40,002,000 |
| Current Liabilities | $19,049,000 | $8,767,000 | $8,803,000 | $1,663,000 |
| Payables And Accrued Expenses | $9,174,000 | $4,322,000 | $5,720,000 | $1,663,000 |
| Payables | $4,190,000 | $1,954,000 | $2,502,000 | $1,450,000 |
| Accounts Payable | $4,190,000 | $1,954,000 | $2,502,000 | $1,450,000 |
| Derivative Product Liabilities | - | - | $4,200,000 | $10,435,000 |
| Equity | ||||
| Common Stock Equity | $484,653,000 | $305,427,000 | $-25,634,000 | $-10,062,000 |
| Total Equity Gross Minority Interest | $484,653,000 | $305,427,000 | $-25,634,000 | $-10,062,000 |
| Stockholders Equity | $484,653,000 | $305,427,000 | $-25,634,000 | $-10,062,000 |
| Gains Losses Not Affecting Retained Earnings | $546,000 | $-522,000 | $4,000 | $0 |
| Other Equity Adjustments | $546,000 | $-522,000 | $4,000 | - |
| Retained Earnings | $-235,228,000 | $-123,745,000 | $-45,438,000 | $-10,652,000 |
| Preferred Securities Outside Stock Equity | - | $0 | $170,778,000 | $40,002,000 |
| Other | ||||
| Ordinary Shares Number | $47,772,567 | $36,580,202 | $35,376,457 | $35,376,457 |
| Share Issued | $47,772,567 | $36,580,202 | $35,376,457 | $35,376,457 |
| Tangible Book Value | $484,653,000 | $305,427,000 | $-25,634,000 | $-10,062,000 |
| Invested Capital | $484,653,000 | $305,427,000 | $-25,634,000 | $-10,062,000 |
| Working Capital | $479,512,000 | $301,035,000 | $142,069,000 | $29,605,000 |
| Capital Lease Obligations | $11,484,000 | $1,476,000 | $2,146,000 | $0 |
| Total Capitalization | $484,653,000 | $305,427,000 | $-25,634,000 | $-10,062,000 |
| Additional Paid In Capital | $719,287,000 | $429,657,000 | $19,796,000 | $586,000 |
| Capital Stock | $48,000 | $37,000 | $4,000 | $4,000 |
| Common Stock | $48,000 | $37,000 | $4,000 | $4,000 |
| Preferred Stock | $0 | $0 | $0 | - |
| Long Term Capital Lease Obligation | $8,729,000 | $739,000 | $1,476,000 | $0 |
| Current Capital Lease Obligation | $2,755,000 | $737,000 | $670,000 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | $7,120,000 | $3,708,000 | $2,413,000 | $0 |
| Current Accrued Expenses | $4,984,000 | $2,368,000 | $3,218,000 | $213,000 |
| Net PPE | $12,885,000 | $4,971,000 | $4,000,000 | $335,000 |
| Accumulated Depreciation | $-1,982,000 | $-965,000 | $-127,000 | $-15,000 |
| Gross PPE | $14,867,000 | $5,936,000 | $4,127,000 | $350,000 |
| Leases | $295,000 | $281,000 | $255,000 | $0 |
| Construction In Progress | $118,000 | $430,000 | $26,000 | $55,000 |
| Other Properties | $14,328,000 | $5,158,000 | $1,719,000 | $295,000 |
| Machinery Furniture Equipment | $126,000 | $67,000 | $43,000 | $0 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $437,894,000 | $248,475,000 | $77,309,000 | $0 |
| Buildings And Improvements | - | $1,442,000 | $2,084,000 | - |
Fetched: 2026-06-18
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Free Cash Flow | |||
| Free Cash Flow | $-88,089,000 | $-67,233,000 | $-28,817,000 |
| Operating Activities | |||
| Operating Cash Flow | $-87,473,000 | $-64,828,000 | $-27,181,000 |
| Cash Flow From Continuing Operating Activities | $-87,473,000 | $-64,828,000 | $-27,181,000 |
| Operating Gains Losses | - | $7,390,000 | $1,124,000 |
| Investing Activities | |||
| Capital Expenditure | $-616,000 | $-2,405,000 | $-1,636,000 |
| Investing Cash Flow | $-187,473,000 | $-170,141,000 | $-78,860,000 |
| Cash Flow From Continuing Investing Activities | $-187,473,000 | $-170,141,000 | $-78,860,000 |
| Financing Activities | |||
| Repurchase Of Capital Stock | $-1,000 | $0 | $-4,000 |
| Issuance Of Capital Stock | $269,439,000 | $221,618,000 | $145,274,000 |
| Financing Cash Flow | $270,786,000 | $221,625,000 | $145,136,000 |
| Cash Flow From Continuing Financing Activities | $270,786,000 | $221,625,000 | $145,136,000 |
| Net Preferred Stock Issuance | $0 | $63,913,000 | $145,220,000 |
| Preferred Stock Issuance | $0 | $63,913,000 | $145,220,000 |
| Net Common Stock Issuance | $269,438,000 | $157,705,000 | $50,000 |
| Common Stock Issuance | $269,439,000 | $157,705,000 | $54,000 |
| Net Other Financing Charges | - | - | $-134,000 |
| Other | |||
| End Cash Position | $52,750,000 | $56,910,000 | $70,254,000 |
| Beginning Cash Position | $56,910,000 | $70,254,000 | $31,159,000 |
| Changes In Cash | $-4,160,000 | $-13,344,000 | $39,095,000 |
| Proceeds From Stock Option Exercised | $1,348,000 | $7,000 | $0 |
| Common Stock Payments | $-1,000 | $0 | $-4,000 |
| Net Investment Purchase And Sale | $-186,857,000 | $-167,736,000 | $-77,224,000 |
| Sale Of Investment | $167,927,000 | $209,796,000 | $0 |
| Purchase Of Investment | $-354,784,000 | $-377,532,000 | $-77,224,000 |
| Net PPE Purchase And Sale | $-616,000 | $-2,405,000 | $-1,636,000 |
| Purchase Of PPE | $-616,000 | $-2,405,000 | $-1,636,000 |
| Change In Working Capital | $3,502,000 | $-2,416,000 | $2,652,000 |
| Change In Other Current Liabilities | $-491,000 | $-670,000 | $-144,000 |
| Change In Other Current Assets | $-791,000 | $83,000 | $-240,000 |
| Change In Payables And Accrued Expense | $8,381,000 | $25,000 | $6,236,000 |
| Change In Accrued Expense | $6,166,000 | $371,000 | $5,380,000 |
| Change In Payable | $2,215,000 | $-346,000 | $856,000 |
| Change In Account Payable | $2,215,000 | $-346,000 | $856,000 |
| Change In Prepaid Assets | $-3,597,000 | $-1,854,000 | $-3,200,000 |
| Other Non Cash Items | $2,032,000 | $8,032,000 | $1,391,000 |
| Stock Based Compensation | $18,855,000 | $10,235,000 | $3,525,000 |
| Amortization Of Securities | $-1,396,000 | $-3,211,000 | $-75,000 |
| Depreciation Amortization Depletion | $1,017,000 | $839,000 | $112,000 |
| Depreciation And Amortization | $1,017,000 | $839,000 | $112,000 |
| Net Income From Continuing Operations | $-111,483,000 | $-78,307,000 | $-34,786,000 |
| Gain Loss On Investment Securities | - | $7,390,000 | $1,124,000 |
| Repayment Of Debt | - | - | $0 |
| Issuance Of Debt | - | - | $0 |
| Net Issuance Payments Of Debt | - | - | $0 |
| Net Long Term Debt Issuance | - | - | $0 |
| Long Term Debt Payments | - | - | $0 |
| Long Term Debt Issuance | - | - | $0 |
Fetched: 2026-06-18